Prothena Corp Public Ltd Co SEC filings PRTA

Prothena Corp Public Ltd Co has 1,006 filings in SEC EDGAR's recent list, going back to Jan 31, 2013. Its latest annual report, Form ARS, was filed on Mar 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.

Prothena Corp Public Ltd Co SEC filings
Form Description Filed Period
ARS Annual report to shareholders Mar 27, 2026 Dec 31, 2025
10-K Annual report Feb 27, 2026 Dec 31, 2025
ARS Annual report to shareholders Mar 28, 2025 Dec 31, 2024
10-K Annual report Feb 27, 2025 Dec 31, 2024
ARS Annual report to shareholders Mar 29, 2024 Dec 31, 2023
10-K Annual report Feb 22, 2024 Dec 31, 2023
ARS Annual report to shareholders Mar 31, 2023 Dec 31, 2022
10-K Annual report Feb 28, 2023 Dec 31, 2022
10-K Annual report Feb 25, 2022 Dec 31, 2021
10-K Annual report Feb 26, 2021 Dec 31, 2020
10-K Annual report Mar 3, 2020 Dec 31, 2019
10-K Annual report Mar 15, 2019 Dec 31, 2018
10-K Annual report Feb 26, 2018 Dec 31, 2017
10-K Annual report Feb 27, 2017 Dec 31, 2016
10-K Annual report Feb 25, 2016 Dec 31, 2015
10-K Annual report Mar 13, 2015 Dec 31, 2014
10-K/A Amended annual report Jun 6, 2014 Dec 31, 2013
10-K Annual report Mar 7, 2014 Dec 31, 2013
10-K Annual report Mar 29, 2013 Dec 31, 2012

Showing 19 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
PRTA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Ireland
Headquarters
Dublin 2, Ireland
SEC filer status
Accelerated filer
SEC CIK
1559053
Former names
Prothena Corp plc (until May 22, 2020); Neotope Corp Ltd (until Oct 1, 2012)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.